DEBIO-0932 + docetaxel

**DEBIO-0932 + docetaxel** is an investigational combination regimen using the oral small molecule Hsp90 inhibitor DEBIO-0932 and the chemotherapy agent docetaxel. - **DEBIO-0932** is a second-generation, orally bioavailable inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone that is abnormally expressed and stabilizes multiple oncogenic proteins in cancer cells. Inhibition of Hsp90 leads to degradation of oncogenic client proteins, resulting in apoptotic cell death and inhibition of tumor growth[1][7]. - **Docetaxel** is a microtubule inhibitor, approved as a chemotherapeutic agent disrupting cell division, primarily used in the treatment of solid tumors such as non-small cell lung cancer (NSCLC), breast cancer, and prostate cancer. Preclinical studies have shown synergistic anti-tumor activity when DEBIO-0932 is combined with docetaxel, with the combination exerting enhanced anti-proliferative effects in vitro and superior tumor suppression in animal xenograft models compared to either agent alone[8]. The combination is being investigated in clinical trials for advanced solid tumors, notably NSCLC and renal cell carcinoma (RCC)[8]. DEBIO-0932 was licensed from Curis and is developed by Debiopharm[4][7].

Other names

debio 0932 + docetaxeldebio0932 + docetaxel